Immunohistochemical Detection of HER-2/neu, c-Kit (CD117) and Vascular Endothelial Growth Factor (VEGF) Overexpression in Soft Tissue Sarcomas

Anil Potti, Apar Kishor P Ganti, Heidi Foster, Stacey Knox, Brian J. Hebert, Ketki K Tendulkar, Kaley Sholes, Michael Koch, Steven Kargas

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Purpose: The aim of this study was to determine the incidence of HER-2/neu, VEGF and CD117 overexpression in soft tissue sarcomas (STS) and to study the effect of this overexpression, if present, on survival in patients with specific histological subtypes of STS. Materials and Methods: We conducted a retrospective observational study on patients diagnosed with STS during the period of 1986-2001. HER-2/neu overexpression was measured in these patients by immunohistochemistry (IHC) using the Hercep test developed by DAKO®. VEGF expression was detected by the avidin-biotin-complex method using Santa Cruz biotechnology (SC 7629). Immunohistochemical staining for c-kit was performed using a 1:250 dilution of the rabbit polyclonal antibody A4502 (IMPATH, CA) with the EnVision detection system. Results: Two hundred and seventy three patients were diagnosed as having STS between 1986 and 2001, however of these patients, only 90 (51 females and 49 males) had enough sample available for testing. Patients who overexpressed VEGF had a significantly shorter survival (23 vs. 52 months; p=0. 01). There was no effect of overexpression of either CD117 or HER-2/neu on survival. Studying the individual histological subtypes we found that, in malignant fibrous histiocytoma, overexpression of either VEGF or CD117 increased survival (41.3 vs. 19.5 months, p=0.01; and 84.5 vs. 17 months, p=0. 006 respectively). In leiomyosarcoma, VEGF overexpression significantly decreased survival (7.5 vs. 76 months, p=0.03), while CD117 overexpression significantly increased survival (70.9 vs. 46.3 months, p=0.03). Conclusion: VEGF overexpression is associated with an adverse outcome in STS. Whether this is true of any particular histological subtype is unclear and needs further investigation. Also, site-specific agents targeting these three bio-markers (alone or with conventional therapy) may have a therapeutic role and need to be elaborated in future clinical trials.

Original languageEnglish (US)
Pages (from-to)333-337
Number of pages5
JournalAnticancer Research
Volume24
Issue number1
StatePublished - Jan 1 2004

Fingerprint

Sarcoma
Vascular Endothelial Growth Factor A
Survival
Malignant Fibrous Histiocytoma
Leiomyosarcoma
Avidin
Biotechnology
Biotin
Observational Studies
Retrospective Studies
Immunohistochemistry
Clinical Trials
Staining and Labeling
Rabbits
Antibodies
Incidence
Therapeutics

Keywords

  • HER-2/neu
  • Soft tissue sarcomas
  • VEGF
  • c-Kit

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Immunohistochemical Detection of HER-2/neu, c-Kit (CD117) and Vascular Endothelial Growth Factor (VEGF) Overexpression in Soft Tissue Sarcomas. / Potti, Anil; Ganti, Apar Kishor P; Foster, Heidi; Knox, Stacey; Hebert, Brian J.; Tendulkar, Ketki K; Sholes, Kaley; Koch, Michael; Kargas, Steven.

In: Anticancer Research, Vol. 24, No. 1, 01.01.2004, p. 333-337.

Research output: Contribution to journalArticle

Potti, Anil ; Ganti, Apar Kishor P ; Foster, Heidi ; Knox, Stacey ; Hebert, Brian J. ; Tendulkar, Ketki K ; Sholes, Kaley ; Koch, Michael ; Kargas, Steven. / Immunohistochemical Detection of HER-2/neu, c-Kit (CD117) and Vascular Endothelial Growth Factor (VEGF) Overexpression in Soft Tissue Sarcomas. In: Anticancer Research. 2004 ; Vol. 24, No. 1. pp. 333-337.
@article{21bbb5f338614801b378f9d8a03221b5,
title = "Immunohistochemical Detection of HER-2/neu, c-Kit (CD117) and Vascular Endothelial Growth Factor (VEGF) Overexpression in Soft Tissue Sarcomas",
abstract = "Purpose: The aim of this study was to determine the incidence of HER-2/neu, VEGF and CD117 overexpression in soft tissue sarcomas (STS) and to study the effect of this overexpression, if present, on survival in patients with specific histological subtypes of STS. Materials and Methods: We conducted a retrospective observational study on patients diagnosed with STS during the period of 1986-2001. HER-2/neu overexpression was measured in these patients by immunohistochemistry (IHC) using the Hercep test developed by DAKO{\circledR}. VEGF expression was detected by the avidin-biotin-complex method using Santa Cruz biotechnology (SC 7629). Immunohistochemical staining for c-kit was performed using a 1:250 dilution of the rabbit polyclonal antibody A4502 (IMPATH, CA) with the EnVision detection system. Results: Two hundred and seventy three patients were diagnosed as having STS between 1986 and 2001, however of these patients, only 90 (51 females and 49 males) had enough sample available for testing. Patients who overexpressed VEGF had a significantly shorter survival (23 vs. 52 months; p=0. 01). There was no effect of overexpression of either CD117 or HER-2/neu on survival. Studying the individual histological subtypes we found that, in malignant fibrous histiocytoma, overexpression of either VEGF or CD117 increased survival (41.3 vs. 19.5 months, p=0.01; and 84.5 vs. 17 months, p=0. 006 respectively). In leiomyosarcoma, VEGF overexpression significantly decreased survival (7.5 vs. 76 months, p=0.03), while CD117 overexpression significantly increased survival (70.9 vs. 46.3 months, p=0.03). Conclusion: VEGF overexpression is associated with an adverse outcome in STS. Whether this is true of any particular histological subtype is unclear and needs further investigation. Also, site-specific agents targeting these three bio-markers (alone or with conventional therapy) may have a therapeutic role and need to be elaborated in future clinical trials.",
keywords = "HER-2/neu, Soft tissue sarcomas, VEGF, c-Kit",
author = "Anil Potti and Ganti, {Apar Kishor P} and Heidi Foster and Stacey Knox and Hebert, {Brian J.} and Tendulkar, {Ketki K} and Kaley Sholes and Michael Koch and Steven Kargas",
year = "2004",
month = "1",
day = "1",
language = "English (US)",
volume = "24",
pages = "333--337",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1",

}

TY - JOUR

T1 - Immunohistochemical Detection of HER-2/neu, c-Kit (CD117) and Vascular Endothelial Growth Factor (VEGF) Overexpression in Soft Tissue Sarcomas

AU - Potti, Anil

AU - Ganti, Apar Kishor P

AU - Foster, Heidi

AU - Knox, Stacey

AU - Hebert, Brian J.

AU - Tendulkar, Ketki K

AU - Sholes, Kaley

AU - Koch, Michael

AU - Kargas, Steven

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Purpose: The aim of this study was to determine the incidence of HER-2/neu, VEGF and CD117 overexpression in soft tissue sarcomas (STS) and to study the effect of this overexpression, if present, on survival in patients with specific histological subtypes of STS. Materials and Methods: We conducted a retrospective observational study on patients diagnosed with STS during the period of 1986-2001. HER-2/neu overexpression was measured in these patients by immunohistochemistry (IHC) using the Hercep test developed by DAKO®. VEGF expression was detected by the avidin-biotin-complex method using Santa Cruz biotechnology (SC 7629). Immunohistochemical staining for c-kit was performed using a 1:250 dilution of the rabbit polyclonal antibody A4502 (IMPATH, CA) with the EnVision detection system. Results: Two hundred and seventy three patients were diagnosed as having STS between 1986 and 2001, however of these patients, only 90 (51 females and 49 males) had enough sample available for testing. Patients who overexpressed VEGF had a significantly shorter survival (23 vs. 52 months; p=0. 01). There was no effect of overexpression of either CD117 or HER-2/neu on survival. Studying the individual histological subtypes we found that, in malignant fibrous histiocytoma, overexpression of either VEGF or CD117 increased survival (41.3 vs. 19.5 months, p=0.01; and 84.5 vs. 17 months, p=0. 006 respectively). In leiomyosarcoma, VEGF overexpression significantly decreased survival (7.5 vs. 76 months, p=0.03), while CD117 overexpression significantly increased survival (70.9 vs. 46.3 months, p=0.03). Conclusion: VEGF overexpression is associated with an adverse outcome in STS. Whether this is true of any particular histological subtype is unclear and needs further investigation. Also, site-specific agents targeting these three bio-markers (alone or with conventional therapy) may have a therapeutic role and need to be elaborated in future clinical trials.

AB - Purpose: The aim of this study was to determine the incidence of HER-2/neu, VEGF and CD117 overexpression in soft tissue sarcomas (STS) and to study the effect of this overexpression, if present, on survival in patients with specific histological subtypes of STS. Materials and Methods: We conducted a retrospective observational study on patients diagnosed with STS during the period of 1986-2001. HER-2/neu overexpression was measured in these patients by immunohistochemistry (IHC) using the Hercep test developed by DAKO®. VEGF expression was detected by the avidin-biotin-complex method using Santa Cruz biotechnology (SC 7629). Immunohistochemical staining for c-kit was performed using a 1:250 dilution of the rabbit polyclonal antibody A4502 (IMPATH, CA) with the EnVision detection system. Results: Two hundred and seventy three patients were diagnosed as having STS between 1986 and 2001, however of these patients, only 90 (51 females and 49 males) had enough sample available for testing. Patients who overexpressed VEGF had a significantly shorter survival (23 vs. 52 months; p=0. 01). There was no effect of overexpression of either CD117 or HER-2/neu on survival. Studying the individual histological subtypes we found that, in malignant fibrous histiocytoma, overexpression of either VEGF or CD117 increased survival (41.3 vs. 19.5 months, p=0.01; and 84.5 vs. 17 months, p=0. 006 respectively). In leiomyosarcoma, VEGF overexpression significantly decreased survival (7.5 vs. 76 months, p=0.03), while CD117 overexpression significantly increased survival (70.9 vs. 46.3 months, p=0.03). Conclusion: VEGF overexpression is associated with an adverse outcome in STS. Whether this is true of any particular histological subtype is unclear and needs further investigation. Also, site-specific agents targeting these three bio-markers (alone or with conventional therapy) may have a therapeutic role and need to be elaborated in future clinical trials.

KW - HER-2/neu

KW - Soft tissue sarcomas

KW - VEGF

KW - c-Kit

UR - http://www.scopus.com/inward/record.url?scp=1442301622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1442301622&partnerID=8YFLogxK

M3 - Article

VL - 24

SP - 333

EP - 337

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1

ER -